A method for quantitatively and indirectly measuring non-fluorine anti-soil chemistry in carpet applications, is based on a known amount of FI trace to be added along with anti-soil chemistry in formulation prior to application to a carpet surface. The anti-soil chemistry with the trace amount of FI is then applied to the carpet through a topical foam or spray applicator during a precoating process. After completion of the precoat process, a carpet sample is collected, carpet face fiber is shaved, and FI is extracted using water. The extracted water solution is used to measure the fluorescence intensity (in counts per second or “CPS”) using a Fluorimeter.

A method for quantitatively and indirectly measuring non-fluorine anti-soil chemistry in carpet applications, is based on a known amount of FI trace to be added along with anti-soil chemistry in formulation prior to application to a carpet surface. The anti-soil chemistry with the trace amount of FI is then applied to the carpet through a topical foam or spray applicator during a precoating process. After completion of the precoat process, a carpet sample is collected, carpet face fiber is shaved, and FI is extracted using water. The extracted water solution is used to measure the fluorescence intensity (in counts per second or “CPS”) using a Fluorimeter.

The disclosure provides, inter alia, alpha-5 beta-1 inhibitors, pharmaceutical compositions comprising alpha-5 beta-1 inhibitors, methods for treating diseases using alpha-5 beta-1 inhibitors, and processes for making alpha-5 beta-1 inhibitors.

The disclosure provides, inter alia, alpha-5 beta-1 inhibitors, pharmaceutical compositions comprising alpha-5 beta-1 inhibitors, methods for treating diseases using alpha-5 beta-1 inhibitors, and processes for making alpha-5 beta-1 inhibitors.

The disclosure provides crystalline forms for certain synthetic intermediates for making belzutifan, a HIF-2α inhibitor, useful for the treatment of cancer. The disclosure also provides processes for isolating the crystalline forms.

##STR00001##

The disclosure provides crystalline forms for certain synthetic intermediates for making belzutifan, a HIF-2α inhibitor, useful for the treatment of cancer. The disclosure also provides processes for isolating the crystalline forms.

##STR00001##

The invention relates to crystals (C) consisting of at least 98% by weight of 4,4′-dichlorodiphenylsulfone, 0 to 2% by weight of impurities and 0 to 2% by weight of at least one solvent (c). Moreover, the present invention relates to a crystal composition (CC) comprising crystals (C) and a process for the production of the crystal composition (CC) and the crystals (C).

The invention relates to crystals (C) consisting of at least 98% by weight of 4,4′-dichlorodiphenylsulfone, 0 to 2% by weight of impurities and 0 to 2% by weight of at least one solvent (c). Moreover, the present invention relates to a crystal composition (CC) comprising crystals (C) and a process for the production of the crystal composition (CC) and the crystals (C).

A method of oxygenating a benzylic C—H bond is provided. The method comprises light induced activation of an initiator and subsequent reaction with oxygen, resulting in the formation of free radicals. Subsequently, free radicals catalyze the reaction of the benzylic C—H bond with oxygen, thereby forming an oxygenated compound.

A method of oxygenating a benzylic C—H bond is provided. The method comprises light induced activation of an initiator and subsequent reaction with oxygen, resulting in the formation of free radicals. Subsequently, free radicals catalyze the reaction of the benzylic C—H bond with oxygen, thereby forming an oxygenated compound.